Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Enrique Diaz-Canton"'
Autor:
Martin Greco, Maximiliano Mestroni, Maximo de la Vega, Gonzalo Recondo, Matias E. Valsecchi, Enrique Diaz Canton
Publikováno v:
Clinical Cancer Drugs. 2:16-28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::332f1bdaa92c4dd3e1321f8771db4653
https://doi.org/10.2174/2212697x02666150203212708
https://doi.org/10.2174/2212697x02666150203212708
Publikováno v:
Clinical Cancer Drugs. 2:38-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3cb6b7d182bb159634a039e23339ed9
https://doi.org/10.2174/2212697x02666150203212942
https://doi.org/10.2174/2212697x02666150203212942
Autor:
Hector Daniel Vuotto, Francisco Bernardo Santillan, Antonio Lorusso, Reinaldo Chacón, Vanesa Romano, Martín Greco, Silvia Adela Avila, Enrique Diaz Canton, Lina Maria Nunez, José Davalos Michel, Florencia Perazzo, Gonzalo Recondo, Eduardo Abalo, María Laura Barrientos, Florencia Cecilia Cardoso, Ignacio Mc Lean, Cristina Noblía, Eduardo Beccar Varela, Oscar G. Mandó, Angela R. Solano, María Viniegra, Gustavo Cortese, Ernesto J. Podestá, Eduardo Gonzalez, Carlos Bas
Publikováno v:
Oncotarget
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
BRCA1/2 mutations in Latin America are scarcely documented and in serious need of knowledge about the spectrum of BRCA pathogenic variants, information which may alter clinical practice and subsequently improve patient outcome. In addition, the searc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7202608cb01523f061243d80cfde7293
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=10814&path[]=34241
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=10814&path[]=34241
Publikováno v:
Reviews on recent clinical trials. 10(2)
Between 20-25% of all breast cancers are diagnosed in patients younger than 50 years of age, most of whom are still premenopausal. Currently, tamoxifen is considered the standard of care for adjuvant treatment in these cases. However, in postmenopaus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6ac4ff189a29a75e316aff9fa79851
https://pubmed.ncbi.nlm.nih.gov/26216437
https://pubmed.ncbi.nlm.nih.gov/26216437
Autor:
Richard Pazdur, Enrique Diaz-Canton
Publikováno v:
Surgical Clinics of North America. 77:211-228
In the mid-1980s, trials of adjuvant therapy for colon cancer in the United States had a "no treatment" arm, which reflected the belief that effective adjuvant chemotherapy did not exist for patients with surgically resected disease at high risk for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57bb6ab1c50792affaa2aeb85a07349
https://doi.org/10.1016/s0039-6109(05)70540-5
https://doi.org/10.1016/s0039-6109(05)70540-5
Publikováno v:
Anti-Cancer Drugs. 7:728-733
We conducted two consecutive phase I clinical trials to identify the qualitative and quantitative toxic effects of uracil-tegafur (UFT) [Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; (BMS-200604) Bristol-Myers Squibb, Princeton, NJ] administered either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e60806695208088b133774a0f6282f
https://doi.org/10.1097/00001813-199609000-00002
https://doi.org/10.1097/00001813-199609000-00002
Publikováno v:
Cancer investigation. 16(3)
UFT [Taiho Pharmaceutical Co. Ltd., Tokyo, Japan; (BMS-200604), Bristol-Myers Squibb, Princeton, NJ], a fluorouracil prodrug, is an oral 4:1 molar concentration of uracil plus tegafur. This study examined the dose-limiting toxic effects and maximum t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc00d47812337997e50743ad6c76f5a7
https://pubmed.ncbi.nlm.nih.gov/9541627
https://pubmed.ncbi.nlm.nih.gov/9541627
Autor:
James L. Abbruzzese, S Graham, Enrique Diaz-Canton, W P Ballard, Susan G. Arbuck, Richard Pazdur, Rodger J. Winn, J E Bradof
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(8)
PURPOSE The camptothecin derivative irinotecan has demonstrated clinical activity in metastatic colorectal carcinoma in both chemotherapy-naive and fluorouracil-refractory patients. 9-Aminocamptothecin (9-AC; NSC 603071), another camptothecin derivat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8890cd46d29c93cd710d8b7aeeb67fa
https://pubmed.ncbi.nlm.nih.gov/9256134
https://pubmed.ncbi.nlm.nih.gov/9256134